BIOAF News Alert Bioasis Technologies (BIOAF) 0.9098 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bioasis Technologies (BIOAF) 0.9098 $BIOAF

biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Marketwire - Thu Sep 18, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB" , announces a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B" of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the "Diagnosis and Therapy of Lysosomal Disorders" research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin.

biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
Marketwire - Tue Sep 09, 8:36AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC" , will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme beta-hexosaminidase subunit beta ("HEXB" , which is functionally deficient in sufferers of Sandhoff Disease.

biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis
Marketwire - Thu Sep 04, 8:04AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces that the Natural Sciences and Engineering Research Council of Canada ("NSERC" has awarded a grant to the University of British Columbia ("UBC" in support of the university's collaborative research and development programs with biOasis Technologies Inc. The University and biOasis continue to develop biOasis' extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier ("BBB" for the potential treatment of previously untreatable Central Nervous System ("CNS" diseases and conditions.

biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds
Marketwire - Fri Aug 29, 5:14PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) (the "Company" is please to announce it has closed its non-brokered private placement announced on August 8th, 2014. The Company has issued 1,694,447 units (each a "Unit" , including an over allotment of 94,477 Units, at a price of CDN$0.95 per unit, for gross proceeds of CDN$1,609,753.15. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$1.20 per share for a period of twelve months up to and including August 29th, 2015, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder's fees of CDN$101,460 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until December 30th, 2014. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business.

WSA Talks to Two Dual-Listed Companies Making Waves
Marketwire - Thu Aug 21, 1:00PM CDT
Wall Street Analyzer's CEO Interview Series

biOasis issues up to 1.6m units in non-brokered private placement
M2 - Mon Aug 11, 3:29AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) reported on Friday the launch of a non-brokered private placement of up to 1,600,000 units.

biOasis Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 8:10PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company" announces a non-brokered private placement of up to 1,600,000 units (each a "Unit" at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant" . Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $1.20 per share for a period of twelve months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 Protection of Minority Security Holders in Special Transactions ("MI 61-101" . The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization.

biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
Marketwire - Fri Jul 25, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose.

biOasis Appoints New Chief Financial Officer and Corporate Secretary
Marketwire - Fri Jun 20, 6:30PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of British Columbia Faculty of Law who also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.

biOasis Enters Investor Relations Agreement with Gale Capital Corporation
Marketwire - Mon Jun 16, 8:02AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company" is pleased to announce that is has retained Gale Capital Corporation ("Gale Capital" effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program.

biOasis awarded patent allowances for Lysosomal Storage Disease therapeutic in Europe and Canada
M2 - Fri Mar 28, 3:37AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) disclosed on Thursday the receipt of notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".

biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Marketwire - Thu Mar 27, 8:03AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 144

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 555

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing First Solar's Options Activity and Market Position

Updated Category News Views 169

Understanding First Solar's Recent Options Activity It's been an intriguing time for traders with First Solar, as financial giants have made noticeable bullish moves associated with the company. Our extensive analysis of the options trading history for First Solar (FSLR) indicates that there have been ten unusual trades, reflecting a significant interest among market...

Continue Reading
Wolters Kluwer's Enablon ESG Excellence Receives 2024 Award

Updated Category News Views 164

Wolters Kluwer’s Enablon ESG Excellence Recognized with Stratus Award Wolters Kluwer has made a significant mark in the information and software solutions industry with its acclaimed Enablon ESG Excellence solution. Recent accolades have highlighted the company as a leader in Software as a Service (SaaS) by the Business Intelligence Group in the prestigious Stratus...

Continue Reading
Insights and Innovations in Software Supply Chain Security

Updated Category News Views 67

Introduction to Kusari Platform The Kusari Platform is a cutting-edge innovation in the realm of software supply chain security. With the ever-increasing complexity of software systems, the need for an effective solution to manage and secure software components is crucial. The Kusari platform is tailored to ingest Software Bill of Materials (SBOM) data, providing...

Continue Reading
Innovative Electronic Street Signs Enhance Public Awareness

Updated Category News Views 332

Revolutionizing Public Communication with Electronic Signs Inventors often seek to enhance the way we communicate essential information to the public, and one such innovative creation is the electronic sign designed for streets. This invention aims to keep residents informed about various conditions such as parking restrictions, storm warnings, accidents, and detours. By...

Continue Reading
Cosmos Health Secures Major Funding for Innovative Strategy

Updated Category News Views 198

Cosmos Health Secures Significant Financing Cosmos Health Inc., a diversified global healthcare group, has recently announced a groundbreaking financing agreement. The company has entered into a securities purchase agreement aiming for up to $300 million in senior secured convertible promissory notes. This strategic move is designed to bolster Cosmos Health's new Ethereum...

Continue Reading